From Vaccine to Pathogen: Modeling Sabin 2 Vaccine Virus Reversion and Evolutionary Epidemiology - Wong, Wesley; Gauld, Jillian; Famulare, Michael (medRxiv, 2020)
The oral poliovirus vaccines (OPV) are one of most effective disease eradication tools in public health. However, the Sabin 2 vaccine strain can revert attenuation and cause outbreaks of circulating, vaccine-derived poliovirus (cVDPV2) that are clinically indistinguishable from wild poliovirus (WPV). Accurately assessing cVDP2 risk requires disentangling the complex interaction between epidemiology and evolutionary biology. Here, we developed a Sabin 2 reversion model that simulates the reversion of Sabin 2 to WPV based on the clinical differences in shedding duration and infectiousness between individuals vaccinated with Sabin 2 and those infected with wild poliovirus. Genetic reversion is informed by a canonical reversion pathway defined by three gatekeeper mutations (A481G, U2909C, and U398C) and the accumulation of genetic load from deleterious nonsynonymous mutations. Our model captures essential aspects of both phenotypic and molecular evolution and simulates transmission using a multiscale transmission model that consolidates the relationships among immunity, susceptibility, and transmission risk. We show that despite the rapid reversion of Sabin 2, cVDPV2 outbreaks can be controlled by maintaining high levels of population-level immunity and sanitation. Supplementary immunization activities must maintain high vaccine coverage to prevent future cVDPV2 outbreaks in the targeted intervention zone, but declining global immunity against Sabin 2 makes them increasingly risky to implement in poor sanitation regions regardless of historical immunization activity. A combined strategy of assessing and improving sanitation levels in conjunction with high coverage vaccination campaigns will limit future cVDPV2 emergence and spread.Significance Statement Since the withdrawal of the Sabin 2 oral poliovirus vaccine (OPV2), circulating vaccine-derived poliovirus outbreaks caused by the genetic reversion of Sabin 2 vaccine virus (cVDPV2) have been increasing in frequency. The current strategies for combating cVDPV2 involve supplemental immunization activities with monovalent Sabin 2 oral poliovirus (mOPV2), which can inadvertently seed future cVDPV2 outbreaks. Accurately assessing future cVDPV2 outbreak risk following mass mOPV2 campaigns is critical poliovirus eradication efforts but must consider the interaction between genetic reversion and epidemiological transmission. We developed an evolutionary epidemiology model to integrate Sabin 2 genetic reversion and transmission into a single framework to evaluate their relative contribution to cVDPV2 outbreaks and inform future intervention strategies.Competing Interest StatementThe authors declare no competing interests during the study. WW, JG, and MF were employed by the funders through the Bill and Melinda Gates Foundation after study completion.Funding StatementFunding was provided by Bill and Melinda Gates through the Global Good Fund. Funders had no role in the study design, data collection, analysis, interpretation, or writing of the manuscript. The corresponding author had full access to all the data in our study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No approval necessary; only public and anonymous data were usedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData Availability Data and code will be made publicly available at https://github.com/InstituteforDiseaseModeling/MultiscaleModeling/tree/evo_epistasis_upon_publication.